Protocol Ledger

NCT05357677 · Phase II · COMPLETED

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

Interventional Phase II clinical trial protocol NCT05357677 sponsored by Shanghai SIMR Biotechnology Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-13 Enrollment: 83 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05357677
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)83 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05357677
Protocol FieldVerified Registry Value
NCT IdentifierNCT05357677
Consolidated Lead SponsorShanghai SIMR Biotechnology Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment83 participants (ACTUAL)
Registered Start Date2022-05-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI